Toxoplasmosis is a contagious illness that is brought on by the parasite Toxoplasma gondii. The strain of Toxoplasma gondii may have an effect on how severe the symptoms of toxo-plasmosis are. Immunocompromised people are more likely to develop neurological, ocular, and systemic diseases as a result of toxoplasmosis. Rosuvastatin® is one of the promising drugs in the treatment of toxoplasmosis. This study determined the rosuvastatin efficacy in treating murine toxoplasmosis. This is being done in an effort to make up for the deficiencies that are present in other standard medications. Mice were divided into 7 groups of 10 mice each. GI: Neither infected nor treated (normal control). GII: Infected, non-treated mice (posi-tive control). GIII: Mice given Spiramycin® as prophylaxis before infection. GIV: Mice given rosuvastatin as prophylaxis before infection. GV: Mice infected and treated by spiramycin af-ter 6th week for 2 weeks. GVI: Mice infected and treated by rosuvastatin after 6th week for 2 weeks. GVII: Following the sixth week, infection was confirmed, and treatment consisted of a combination of rosuvastatin and spiramycin for two weeks. Histological examination of brain and liver, and counting brain cysts, were used to evaluate the efficacy of treatment.
The results showed that rosuvastatin treated group showed significant reduction in brain cysts and improved histopathological picture in brain and liver tissue. Combination of rosu-vastatin and spiramycin gave the best results in reduction of brain cysts number and the least pathological changes in brain and liver tissue. The effect of rosuvastatin was augmented after combination with spiramycin. |
